North Carolina is currently home to 2672 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Durham, Charlotte, Winston-Salem and Chapel Hill. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Advancing Vaccine Equity Through Understanding Vaccine Hesitancy, Barriers, and Trust
NCT05537714
Recruiting
In the proposed study, the investigators will conduct qualitative interviews and focus groups with Black, Hispanic, and medically underserved communities, living in the rural south and will provide a quantitative survey (mixed methods) to identify reasons for vaccine hesitancy, including any structural barriers experienced by this population. The investigators will assess what vaccination messaging was received by trusted individuals and how this messaging may have impacted vaccination behavior.... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
09/25/2023
Locations: East Carolina University, Greenville, North Carolina
Conditions: Vaccine Hesitancy, Structural Barriers, Vaccine Trust
Register for Updates
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Preserved Ejection Fraction
NCT06061549
Recruiting
The goal of this clinical trial is to test an experimental gene therapy in participants with heart failure with preserved ejection fraction, also known as diastolic heart failure. The main questions it aims to answer are: safety and tolerability of the gene therapy; and whether the gene therapy helps the heart ventricles relax during filling. Participants will undergo a one-time infusion of the gene therapy in the cardiac catheterization laboratory and then be followed for safety and effects on... Read More
Gender:
All
Ages:
50 years and above
Trial Updated:
09/23/2023
Locations: Duke University, Durham, North Carolina
Conditions: Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction
Register for Updates
OPN-375 Efficacy and Safety in Adolescents With Bilateral Nasal Polyps
NCT03747458
Recruiting
This is a 16-Week Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of OPN-375 186 μg Twice a Day (BID) in Adolescents with Bilateral Nasal Polyps followed by a 12-Week Open-Label Treatment Phase. The total planned number of subjects is approximately 120 adolescents (12-17 years of age) who will be randomly assigned to receive 1 of 2 study treatments using a 2:1 ratio (OPN-375 186 μg: Placebo). For the PK sub-study, up to 14 subjec... Read More
Gender:
All
Ages:
Between 12 years and 17 years
Trial Updated:
09/22/2023
Locations: Allergy Asthma & Immunology Research Institute, Charlotte, North Carolina
Conditions: Bilateral Nasal Polyposis
Register for Updates
Conditioning SCID Infants Diagnosed Early
NCT03619551
Recruiting
The investigators want to study if lower doses of chemotherapy will help babies with SCID to achieve good immunity with less short and long-term risks of complications after transplantation. This trial identifies babies with types of immune deficiencies that are most likely to succeed with this approach and offers them transplant early in life before they get severe infections or later if their infections are under control. It includes only patients receiving unrelated or mismatched related dono... Read More
Gender:
All
Ages:
Between 0 years and 2 years
Trial Updated:
09/15/2023
Locations: Levine Children's Hospital, Charlotte, North Carolina
Conditions: SCID
Register for Updates
The Efficacy and Safety of Bonjesta® for Nausea and Vomiting of Pregnancy in Pregnant Adolescents
NCT05289557
Recruiting
The primary objective of this study is to compare the efficacy of Bonjesta for the treatment of nausea and vomiting of pregnancy (NVP) in pregnant adolescents aged 12 to 17 years with placebo. The secondary objective of this study is to compare the safety of Bonjesta in pregnant adolescents aged 12 to 17 years with placebo.
Gender:
Female
Ages:
Between 12 years and 17 years
Trial Updated:
09/08/2023
Locations: Unified Women's Clinical Research, Winston-Salem, North Carolina
Conditions: Morning Sickness
Register for Updates
Use of AC5® Advanced Wound System in the Treatment of Diabetic Foot Ulcers
NCT06028386
Recruiting
The purpose of this clinical evaluation is to collect and compare outcomes data from patients with UT 1A diabetic foot ulcers treated with 510K FDA cleared, commercially available self-assembling peptide, AC5®Advanced Wound System, as compared to an advanced standard of care. Patient outcomes will be compared at the end of the study.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/07/2023
Locations: Dr. Christopher Gauland, Greenville, North Carolina
Conditions: Non-healing Wound, Diabetic Foot Ulcer
Register for Updates
Autologous Adipose-derived Stromal Vascular Fraction for Treatment of Knee Osteoarthritis
NCT04440189
Recruiting
This study is a pivotal study to evaluate the efficacy and safety of a single injection of autologous adipose-derived SVF produced using the GID SVF-2 device system for treatment of pain with concomitant improvement in function associated with osteoarthritis of the knee joint.
Gender:
All
Ages:
Between 35 years and 85 years
Trial Updated:
09/07/2023
Locations: OrthoCarolina Research Institute, Charlotte, North Carolina
Conditions: Osteoarthritis, Knee
Register for Updates
Study of 3D Scanning for Adolescent Scoliosis
NCT06035952
Recruiting
The investigators aim to validate three-dimensional topographical scanning technology as a tool for evaluation of scoliosis. Through the incorporation of 3D topographical technology in the measurement of deformity, the investigators hope to validate a novel approach to quantify deformity progression and provide an accessible alternative to traditional radiographic workup.
Gender:
All
Ages:
Between 10 years and 18 years
Trial Updated:
09/06/2023
Locations: Duke University, Durham, North Carolina
Conditions: Scoliosis
Register for Updates
A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative Colitis
NCT05181137
Recruiting
This is a randomized, double-blind, placebo-controlled, multicenter Phase 3 study that will enroll approximately 368 subjects aged 18 to 75 years old with Moderately to Severely Active Ulcerative Colitis.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
09/01/2023
Locations: University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
Conditions: Ulcerative Colitis
Register for Updates
AltaValve Early Feasibility Study Protocol
NCT03997305
Recruiting
Prospective, single-arm, multicenter study to evaluate the safety and performance of the AltaValve for the treatment of moderate to severe or severe mitral valve regurgitation in subjects who are considered high risk for mortality and morbidity from conventional open-heart surgery.
Gender:
All
Ages:
18 years and above
Trial Updated:
08/31/2023
Locations: Atrium Health, Charlotte, North Carolina
Conditions: Mitral Regurgitation, Mitral Insufficiency, Mitral Valve Incompetence, Mitral Valve Regurgitation, Mitral Incompetence
Register for Updates
A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/Control
NCT05705440
Recruiting
The purpose of this follow-up study is to describe the safety in subsequent pregnancies in participants who were previously administered the RSVPreF3 maternal vaccine or control during any prior RSV MAT study. The study participants enrolled in this follow-up study received RSVPreF3 maternal vaccination (any dose) or controls during the following prior RSV MAT studies: RSV MAT-001 (NCT03674177), RSV MAT-004 (NCT04126213), RSV MAT-010 (NCT05045144), RSV MAT-011 (NCT04138056), RSV MAT-009 (NCT046... Read More
Gender:
Female
Ages:
Between 9 years and 49 years
Trial Updated:
08/30/2023
Locations: GSK Investigational Site, Hendersonville, North Carolina
Conditions: Respiratory Syncytial Virus Infections
Register for Updates
Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients
NCT05586958
Recruiting
The aim of this 6-month randomized multi-regional double-blind parallel group placebo-controlled phase 3 study is to assess the efficacy and safety of three different doses of Tigulixostat in gout patients with hyperuricemia.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
08/24/2023
Locations: Triad Clinical Trials, Greensboro, North Carolina
Conditions: Gout, Hyperuricemia, Gout Flare, Tophi
Register for Updates